Light has always been known for providing us with visual clarity. However, in living organisms, specific types of light can cause cells to respond in a measurable way. Photobiomodulation is a term that developed in the last 20 years after several researches have demonstrated that light at low power densities can find its way to […]
The post How Low-Level Light Exposure Influences Cellular Repair Mechanisms appeared first on Medical News Bulletin.
Decentering the “Primary Care Is a Place” Paradigm: A Bridge to Whole-Person Care Healthcare is evolving. In recent years patients and providers alike have questioned whether treating symptoms alone is sufficient. Integrative medicine has arisen to address this transition, providing a model in which conventional medical treatments and evidence-based complementary therapies can coexist. Instead of treating itself as […]
The post Integrative Medicine in Modern Healthcare: What Does the Research Say? appeared first on Medical News Bulletin.
Chronic Venous Insufficiency (CVI) is a very widespread, but largely underestimated vascular disorder that involves millions of people throughout the world. Defined by inability of the venous system in lower extremities to bring blood back toward the heart CVI occurs when the vein valves weaken, allowing reflux and accumulation of blood in legs. Chronic venous disease: as […]
The post Chronic Venous Insufficiency: Emerging Research and Modern Treatment Approaches appeared first on Medical News Bulletin.
PHILADELPHIA — Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
These findings suggest that treatment with barzolvolimab may modify disease, Martin Metz, MD, head of translational research, Charité University Medicine, Berlin, and colleagues wrote.
“Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of CSU — the mast cell,” Diane Young, MD, senior vice president and chief
PHILADELPHIA — Among patients aged 2 to 17 years with moderate to severe atopic dermatitis, tapinarof cream 1% significantly improved sleep, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“In my clinical experience, severe itching and sleep disruption are especially burdensome for patients with AD, so these data have the potential of being particularly impactful,” Druhan L. Howell, MD, adjunct professor and pediatrics program director in the department of internal medicine at the University of South Alabama, told Healio.
In a sub-analysis
The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.
Somapacitan-beco (Sogroya, Novo Nordisk) is now approved for children aged 2.5 years and older with idiopathic short stature, short stature born small for gestational age and no catch-up growth by age 2, and growth failure associated with Noonan syndrome, according to the release.
Somapacitan-beco was previously approved for adults with growth hormone deficiency and children aged 2.5 years and older with growth